We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy
Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
The UK is advancing in vivo CRISPR gene editing beyond ex vivo models. Explore regulatory signals, lipid nanoparticle delivery, and NHS reimbursement challenges.
By Dr. Eleanor Vance, Regulatory Affairs Editor
NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because
By Tom Okafor, Clinical Trials Correspondent
Oral morphine sulphate supplied as Oramorph remains a first-line strong opioid when moderate to severe pain does not respond to weaker agents. The immediate release formulation supports fast onset, sh
By James Whitfield, Manufacturing & Supply Chain Writer
Subscribe to our weekly pharmaceutical intelligence digest